NCT05010863 Gastric Cancer Marker Detection and Its Kit Development
| NCT ID | NCT05010863 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Condition | Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 530 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2023-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 530 participants in total. It began in 2021-01-01 with a primary completion date of 2023-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The gastric cancer diagnosis and treatment specifications clearly point out that tumor markers need to be detected in the process of diagnosis, efficacy evaluation and follow-up. However, there is currently a lack of gastric cancer markers with high sensitivity and specificity, and the detection of markers is limited to a single index analysis, which has many shortcomings such as long analysis time, large reagent consumption, and high detection cost. Therefore, this project will use protein chips to detect new types of gastric cancer patient markers and establish a multi-diagnostic model for early screening of gastric cancer. Finally, monoclonal antibodies will be produced against various high-specific tumor markers and a gastric cancer diagnostic kit will be established.
Eligibility Criteria
Inclusion Criteria: patient 1. Age is greater than or equal to 18 years old (including 18 years old); 2. Patients who are diagnosed with cancer after pathological diagnosis; 3. Can provide enough tissue samples; 4. Have not received anti-tumor treatment in the past; 5. Comply with the principle of informed consent and sign the informed consent form. healthy person: 1. Age is greater than or equal to 18 years old (including 18 years old); 2. No underlying disease; 3. Can provide enough tissue samples; 4. Comply with the principle of informed consent and sign the informed consent form. Exclusion Criteria: 1. The tumor foci cannot be clearly derived from a specific tumor type; 2. Those who have a history of other tumors, autoimmune diseases and allergies; 3. Previously received anti-tumor treatments such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy or Chinese medicines with anti-cancer and anti-tumor effects in the instructions; 4. Participated in any clinical trial within 90 days before the experiment; 5. Received major surgery within 90 days before the experiment; 6. Received bone marrow transplantation 90 days before the experiment; 7. Subjects who may not be able to complete the study due to other reasons or who are determined by the investigator to be unsuitable to participate in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05010863 clinical trial?
This trial is open to participants of all sexes, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05010863 currently recruiting?
Yes, NCT05010863 is actively recruiting participants. Contact the research team at fame198288@126.com for enrollment information.
Where is the NCT05010863 trial being conducted?
This trial is being conducted at Wenzhou, China.
Who is sponsoring the NCT05010863 clinical trial?
NCT05010863 is sponsored by Second Affiliated Hospital of Wenzhou Medical University. The trial plans to enroll 530 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.